Hence, our results evidently suggest that specific elimination of SPINK1 from the whole spectrum of SASP in the treatment-damaged TME increases tumour response to chemotherapy, a result independent of androgen response or AR signaling of prostate tumours per se. The gene discussed is SPINK1; the disease is neoplasm.